Gland Pharma Share Price Today (GLAND)
TODAY IN ONE LINE
GLAND is little changed at ₹2428.30 on light volume — a quiet consolidation day, supported by recent strong earnings.
With a market cap of ₹40,034.06 Cr., it trades at a P/E of 39.05. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Gland Pharma flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 96.4% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 22.3% and Profit up 96.6%
- ●High Capital EfficiencyROCE of 15.1% indicating pricing power
- ●Healthy Operating MarginsOPM is structurally strong at 25.3%
- ●High Promoter HoldingPromoters hold 51.8% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Gland Pharma News
What changed recently?
Recent events, corporate actions, and announcements.
Gland Pharma Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Gland Pharma Limited, framed against the sector median so the premium or discount is obvious at a glance.
Gland Pharma Limited trades at a P/E of 39.05× and P/B of 3.87×, against the Healthcare sector median P/E of 40.97×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Gland Pharma Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Gland Pharma Limited — derived from the live tape, not yesterday's close.
Gland Pharma Limited last traded at ₹2,428.3 with an intraday range of ₹2,408.8–₹2,459.9 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹2428.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2558.07 | +129.77 | +5.34% |
| R3 | 2506.97 | +78.67 | +3.24% |
| R2 | 2483.43 | +55.13 | +2.27% |
| R1 | 2455.87 | +27.57 | +1.14% |
| PIVOT | 2432.33 | 4.03 | 0.17% |
| CURRENT | 2428.30 | — | — |
| S1 | 2404.77 | -23.53 | -0.97% |
| S2 | 2381.23 | -47.07 | -1.94% |
| S3 | 2353.67 | -74.63 | -3.07% |
| S4 | 2302.57 | -125.73 | -5.18% |
GLAND is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹2408.8–₹2446.2
Trading Inside opening range
Gland Pharma Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Gland Pharma Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Gland Pharma Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹40,034.06 Cr. and reported EPS of ₹62.35.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 5,617 | 6,431 ▲ 14.5% |
| Sales Growth YoY %Derived | -0.85% | 14.50% |
| Other Income | 214 | 316 ▲ 48.1% |
| Total Income | 5,830 | 6,747 ▲ 15.7% |
| 2,090 | 2,243 ▲ 7.3% | |
| Gross ProfitDerived | 3,526 | 4,188 ▲ 18.8% |
| Gross Margin %Derived | 62.78% | 65.12% |
| 2,257 | 2,558 ▲ 13.3% | |
| EBITDA (Operating Profit)Derived | 1,269 | 1,630 ▲ 28.4% |
| OPM %Derived | 22.59% | 25.34% |
| 420 | 433 ▲ 3.0% | |
| Profit Before Tax (PBT) | 1,063 | 1,465 ▲ 37.8% |
| 364 | 437 ▲ 20.1% | |
| Effective Tax %Derived | 34.27% | 29.86% |
| Total Profit for Period | 699 | 1,027 ▲ 47.1% |
| Net Profit (Owner's PAT)Derived | 699 | 1,027 ▲ 47.1% |
| Net Profit Margin %Derived | 12.44% | 15.98% |
| PAT Growth YoY %Derived | -9.57% | 47.07% |
| Earnings Per Share (EPS ₹) | 42.40 | 62.35 ▲ 47.1% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 55 | 431 ▲ 678.1% |
| Total Expenses (incl. D&A & Interest) | 4,767 | 5,282 ▲ 10.8% |
| Material Cost % of RevenueDerived | 35.12% | 34.83% |
| Employee Cost % of RevenueDerived | 24.95% | 25.33% |
| Other Cost % of RevenueDerived | 15.23% | 14.45% |
| Interest Coverage (x)Derived | 21.22x | 36.24x |
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,463 | 4,401 ▲ 27.1% | 3,625 ▼ 17.6% | 5,665 ▲ 56.3% | 5,617 ▼ 0.9% | 6,431 ▲ 14.5% | |
| Sales Growth YoY %Derived | — | 27.08% | -17.64% | 56.29% | -0.85% | 14.50% | |
| Other Income | 135 | 224 ▲ 66.2% | 240 ▲ 7.4% | 170 ▼ 29.2% | 214 ▲ 25.5% | 316 ▲ 48.1% | |
| Total Income | 3,598 | 4,625 ▲ 28.5% | 3,865 ▼ 16.4% | 5,835 ▲ 51.0% | 5,830 ▼ 0.1% | 6,747 ▲ 15.7% | |
1,492 | 2,109 ▲ 41.4% | 1,685 ▼ 20.1% | 2,173 ▲ 28.9% | 2,090 ▼ 3.8% | 2,243 ▲ 7.3% | ||
| Gross ProfitDerived | 1,971 | 2,291 ▲ 16.3% | 1,939 ▼ 15.4% | 3,492 ▲ 80.1% | 3,526 ▲ 1.0% | 4,188 ▲ 18.8% | |
| Gross Margin %Derived | 56.92% | 52.07% | 53.50% | 61.64% | 62.78% | 65.12% | |
669 | 781 ▲ 16.8% | 914 ▲ 17.0% | 2,159 ▲ 136.1% | 2,257 ▲ 4.6% | 2,558 ▲ 13.3% | ||
| EBITDA (Operating Profit)Derived | 1,302 | 1,510 ▲ 16.0% | 1,025 ▼ 32.1% | 1,333 ▲ 30.1% | 1,269 ▼ 4.8% | 1,630 ▲ 28.4% | |
| OPM %Derived | 37.61% | 34.32% | 28.27% | 23.53% | 22.59% | 25.34% | |
102 | 116 ▲ 13.1% | 98 ▼ 15.4% | 371 ▲ 279.4% | 420 ▲ 13.2% | 433 ▲ 3.0% | ||
| Profit Before Tax (PBT) | 1,335 | 1,619 ▲ 21.3% | 1,055 ▼ 34.8% | 1,133 ▲ 7.4% | 1,063 ▼ 6.2% | 1,465 ▲ 37.8% | |
338 | 407 ▲ 20.4% | 274 ▼ 32.8% | 360 ▲ 31.6% | 364 ▲ 1.1% | 437 ▲ 20.1% | ||
| Effective Tax %Derived | 25.31% | 25.14% | 25.94% | 31.79% | 34.27% | 29.86% | |
| Total Profit for Period | 997 | 1,212 ▲ 21.5% | 781 ▼ 35.5% | 772 ▼ 1.1% | 699 ▼ 9.6% | 1,027 ▲ 47.1% | |
| Net Profit (Owner's PAT)Derived | 997 | 1,212 ▲ 21.5% | 781 ▼ 35.5% | 772 ▼ 1.1% | 699 ▼ 9.6% | 1,027 ▲ 47.1% | |
| Net Profit Margin %Derived | 28.79% | 27.53% | 21.55% | 13.64% | 12.44% | 15.98% | |
| PAT Growth YoY %Derived | — | 21.54% | -35.54% | -1.10% | -9.57% | 47.07% | |
| Earnings Per Share (EPS ₹) | 60.94 | 73.75 ▲ 21.0% | 47.42 ▼ 35.7% | 46.90 ▼ 1.1% | 42.40 ▼ 9.6% | 62.35 ▲ 47.1% | |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.4% | 16 ▲ 0.2% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | -0 ▲ 47.5% | -1 ▼ 214.0% | -8 ▼ 446.9% | 55 ▲ 804.2% | 431 ▲ 678.1% | |
| Total Expenses (incl. D&A & Interest) | 2,263 | 3,006 ▲ 32.8% | 2,810 ▼ 6.5% | 4,702 ▲ 67.3% | 4,767 ▲ 1.4% | 5,282 ▲ 10.8% | |
| Material Cost % of RevenueDerived | 50.51% | 46.51% | 47.36% | 35.70% | 35.12% | 34.83% | |
| Employee Cost % of RevenueDerived | 8.99% | 7.69% | 11.13% | 22.19% | 24.95% | 25.33% | |
| Other Cost % of RevenueDerived | 10.32% | 10.06% | 14.10% | 15.92% | 15.23% | 14.45% | |
| Interest Coverage (x)Derived | 352.81x | 267.05x | 117.90x | 37.73x | 21.22x | 36.24x |
Gland Pharma segment analysis : revenue and profit mix.
Disclosed business segments at Gland Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Gland Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Gland Pharma Limited.
Our AI distills the core fundamental drivers supporting Gland Pharma Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Gland Pharma Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 96.6% YoY, reflecting exceptional earnings acceleration momentum.
TTM revenue growth of 22.3% significantly outpaces most pharmaceutical sector peers.
Operating margin of 18.75% demonstrates robust profitability and strong pricing power.
Debt-to-equity ratio of 0.0003x ensures fortress-like financial flexibility and stability.
Promoter holding of 51.83% signals strong management commitment and aligned governance.
Key Risks.
P/E ratio of 39.68x is elevated, suggesting premium valuation and high growth expectations.
Dividend yield of 0.84% is low, unattractive for income-focused investors seeking returns.
ROE of 10.70% lags peer benchmarks, indicating moderate capital efficiency and returns.
ROCE of 15.10% below sector averages, limiting reinvestment returns on deployed capital.
FII holdings eased from 23.90% to 19.16%, signaling foreign investor caution and concern.
Flip Conditions.
Valuation risk. a P/E above 51 (~1.2× the sector multiple of 41.0) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.42%.
Gland Pharma Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Gland Pharma Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Gland Pharma Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Gland Pharma Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Gland Pharma Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Gland Pharma Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Gland Pharma Limited stood at 54.5% of traded volume, against a 20-day average of 53.3%.
Gland Pharma announcements: results, concalls, ratings, M&A.
Filings Gland Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Gland Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 157 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Gland Pharma Limited has informed the Exchange about Schedule of meet
Change in Director(s)
Gland Pharma Limited has informed the Exchange regarding Change in Director(s) of the company.
Shareholders meeting
Gland Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding…
Action(s) taken or orders passed
Gland Pharma Limited has informed the Exchange about Action(s) taken or orders passed
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Gland Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Updates
Gland Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Gland Pharma has declared, sequenced by announce and record date.
Gland Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Gland Pharma insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Gland Pharma as reported to SEBI — buying and selling signals from the people who know the business best.
Gland Pharma insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| S SRINIVASA RAO | Insider | 26 Feb 2025 | buy | +2.8 K | ₹15.18 L | ₹542.00 |
About Gland Pharma Limited: business, sector, key facts.
What Gland Pharma Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Gland Pharma Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GLAND, BSE: 543245.
Gland Pharma Limited is a prominent pharmaceutical company specializing in the manufacturing and sale of injectable formulations. Its global reach extends to India, the United States, Europe, Canada, Australia, New Zealand, and other international markets, showcasing a significant international presence and distribution network. The company's business model centers around providing a diverse range of injectable medications to meet various therapeutic needs.
A core aspect of Gland Pharma's operations involves the research and development of active pharmaceutical ingredients (APIs). This includes the complex synthesis of molecules such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. This in-house capability allows for greater control over the quality and supply chain of their products, and signifies a commitment to innovation within the pharmaceutical sector.
The company's product portfolio caters to a wide spectrum of therapeutic areas. This includes anti-malarial, anti-infectives, anti-neoplastic, blood-related, cardiac, gastrointestinal, gynecological, hormonal, neuro/CNS, ophthalmological/otological, pain and analgesic, respiratory medications, and vitamins, minerals, and nutrient supplements. The breadth of therapeutic categories serviced indicates a commitment to addressing a variety of patient needs and healthcare challenges.
Beyond manufacturing and sales, Gland Pharma also offers contract development services. This suggests that the company not only produces its own injectable medications but also provides research and development support to other pharmaceutical entities. This additional revenue stream diversifies the company’s income and expands its role within the industry ecosystem.
Established in 1978 and headquartered in Hyderabad, India, Gland Pharma operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd. This affiliation with a larger parent company provides financial backing and potentially access to broader resources and markets, contributing to the company's ongoing success and expansion.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Gland Pharma Limited (GLAND).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Gland Pharma Limited (GLAND)?
The current share price of Gland Pharma Limited (GLAND) is ₹2,428.3. Today, the stock has gained by ₹1.20 (0.05%), trading in a range of ₹2,408.8 to ₹2,459.9. The stock opened at ₹2,429 with a trading volume of 1,42,915 shares.
02Is Gland Pharma Limited stock a good investment for long-term?
Gland Pharma Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹40,034.06 crores, P/E ratio of 39.05, ROE of 10.70%, and ROCE of 15.10%. The dividend yield stands at 0.84%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Gland Pharma Limited stock?
The 52-week high price of Gland Pharma Limited (GLAND) is ₹2,573.5, while the 52-week low is ₹1,573.6. Currently trading at ₹2,428.3, the stock is 85.5% away from its 52-week low and 5.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Gland Pharma Limited stock at the current price?
Whether to buy Gland Pharma Limited stock at ₹2,428.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 39.05 and P/B ratio of 3.87. Today's performance shows a gain of 0.05%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Gland Pharma Limited and when is the next dividend?
Gland Pharma Limited offers a dividend yield of 0.84%, which means for every ₹100 invested at the current price of ₹2,428.3, you can expect to receive approximately ₹0.84 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Gland Pharma Limited?
Gland Pharma Limited's key financial metrics include: P/E Ratio: 39.05, P/B Ratio: 3.87, ROE: 10.70%, ROCE: 15.10%, Dividend Yield: 0.84%, EPS: ₹62.35, Book Value: ₹628.81, and Debt-to-Equity: 0.03. The company's market cap stands at ₹40,034.06 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Gland Pharma Limited stock performing today in the market?
Gland Pharma Limited stock opened at ₹2,429 and is currently trading at ₹2,428.3, showing a gain of ₹1.20 (0.05%). The intraday high is ₹2,459.9 and low is ₹2,408.8. The trading volume stands at 1,42,915 shares, indicating moderate market participation today.
08What is the P/E ratio of Gland Pharma Limited and what does it indicate?
Gland Pharma Limited has a Price-to-Earnings (P/E) ratio of 39.05, which means investors are willing to pay ₹39.05 for every ₹1 of earnings. With an EPS of ₹62.35, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Gland Pharma Limited (GLAND) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.